• S2Medical posted H1 net sales of SEK 7.4 million, up 7.25% year over year.
• Operating profit swung to SEK 0.2 million from an operating loss, on higher Abena-linked sales and core products.
• Net profit was unchanged at SEK 0.2 million; EPS was SEK 0.00.
• Cash fell to SEK 0.6 million; H1 cash flow was SEK -0.3 million.
• Validated European patent EP 4056195 in 18 countries through February 2039; shareholders backed share issues targeting about SEK 2.9 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. S2Medical AB (publ) published the original content used to generate this news brief on August 21, 2026, and is solely responsible for the information contained therein.